Potential Immunotherapeutics for Immunosuppression in Sepsis

Area of Science:

• Immunology
• Critical Care Medicine
• Infectious Diseases

Background:

• Sepsis, a severe infection response, initially causes hyper-inflammation leading to organ dysfunction.
• Improved early interventions have reduced acute sepsis mortality.
• Late-phase sepsis mortality remains high due to sepsis-induced immunosuppression.

Purpose of the Study:

• To investigate the mechanisms of late-phase sepsis mortality.
• To explore therapeutic strategies targeting immune system recovery in sepsis survivors.
• To address the challenge of long-term mortality in sepsis.

Main Methods:

• Review of current literature on sepsis pathophysiology and treatment.
• Analysis of immune status in sepsis survivors.
• Evaluation of immune-enhancing molecules and strategies.

Main Results:

• Sepsis survivors often exhibit immunosuppression (tolerance, exhaustion, apoptosis).
• This compromised immune state increases susceptibility to nosocomial and opportunistic infections.
• These secondary infections are a major cause of late-phase mortality.

Conclusions:

• Late-phase mortality in sepsis is driven by immune dysfunction, not initial inflammation.
• Therapeutic approaches are shifting towards reversing immunosuppression.
• Targeting immune enhancement offers a promising strategy to reduce long-term sepsis mortality.